Search for: [Abstract = "on in HepG2 hepatocytes in the NAFLD model. Furthermore, most of the active complexes from both groups showed better effects in the used models than the BMOV complex. Complexes from both groups activated AKT and ERK signaling pathways in hepatocytes to a comparable extent. One of the ONO\-type complex, VC068, exhibited activity in all the aforementioned models and also increased glucose consumption in C2C12 myocytes. It also reversed the impaired transport of \[14C\]\-deoxy\-D\-glucose into HepG2 hepatocytes caused by insulin resistance. The selected representative ONO\-type complex, VC036, significantly enhanced adipogenesis in 3T3\-L1 adipocytes to a greater extent than rosiglitazone. However, this complex did not affect the reduction of intracellular lipid content in fully differentiated adipocytes with high lipid content. In glucose consumption tests conducted on these cells, the VC067 complex showed no activity, unlike the VC048 complex, despite both ONO\-type complexes having a high inhibition of PTP1B. Differences in the activity were identified both between the entire groups of ONO and ONS complexes and within each group. Certain structural characteristics were also indicated to be associated with these effects. The observed differences in the effects of ONS and ONO complexes in different models and cellular mechanisms may stem from the specific or selective act"]

Number of results: 1